Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
The Lancet. Infectious Diseases|October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen, Franco Maggiolo, José R Arribas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2012
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trialCatherine Fagard, Céline Colin, Charlotte Charpentier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2008
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infectionJulio Montaner, Patrick Yeni, Nathan N Clumeck, et al.
Plos One|August 13, 2013
Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohortsEvguenia Krastinova, Remonie Seng, Patrick Yeni, et al.
AIDS (London, England)|March 22, 2017
Budget impact of antiretroviral therapy in a French clinic cohortEmmanuelle Papot, Roland Landman, Françoise Louni, et al.
AIDS (London, England)|February 16, 2007
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1Christine Katlama, Roberto Esposito, Jose M Gatell, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2012
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo)Véronique Joly, Catherine Fagard, Carine Grondin, et al.
Antiviral Therapy|May 12, 2004
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study)Claire Lamotte, Roland Landman, Gilles Peytavin, et al.
Antimicrobial Agents and Chemotherapy|May 23, 2002
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial)Véronique Joly, Philippe Flandre, Vincent Meiffredy, et al.
Antiviral Therapy|October 29, 2014
Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infectionJoseph J Eron, David A Cooper, Roy T Steigbigel, et al.
Pageof 7